SAN DIEGO, June 8, 2017 /PRNewswire/ -- Pfenex Inc.
(NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in
the development of biosimilar therapeutics, including high value
and difficult to manufacture proteins, today announced that it will
be presenting at the 2017 JMP Healthcare Conference at the St.
Regis Hotel in New York, NY on
Wednesday June 21st at
11:30 am ET. A live audio
webcast and archive of the presentation will be available in the
Investor Relations section of the Pfenex Website at
www.pfenex.com.
About Pfenex Inc.
Pfenex Inc. is a clinical-stage
biotechnology company engaged in the development of biosimilar
therapeutics and high-value and difficult to manufacture proteins.
The Company's lead product candidates are PF708, a therapeutic
equivalent candidate to Forteo (teriparatide) for the treatment of
osteoporosis, and PF582, a biosimilar candidate to Lucentis
(ranibizumab), for the potential treatment of patients with retinal
diseases. Pfenex has leveraged its Pfēnex Expression
Technology® platform to build a pipeline of
product candidates and preclinical products under development
including other biosimilars, as well as vaccines, therapeutic
equivalents to reference listed drug products, and next generation
biologics.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/pfenex-to-present-at-the-2017-jmp-healthcare-conference-300470794.html
SOURCE Pfenex Inc.